Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.

Open access

Abstract

BACKGROUND: Observational and laboratory studies suggest that some hormonal contraceptive methods, particularly intramuscular depot medroxyprogesterone acetate (DMPA-IM), might increase women's susceptibility to HIV acquisition. We aimed to compare DMPA-IM, a copper intrauterine device (IUD), and a levonorgestrel (LNG) implant among African women seeking effective contraception and living in areas of high HIV incidence. METHODS: We did a randomised, multicentre, open-label trial across 12 research sites in eSwatini, Kenya, South Africa, and Zambia. We included HIV-seronegative women aged 16-35 years who were seeking effective contraception, had no medical contraindications to the trial contraceptive methods, agreed to use the assigned method for 18 months, and reported not using injectable, intrauterine, or implantable contraception for the previous 6 months. Participants were randomly assigned (1:1:1) to receive an injection of 150 mg/mL DMPA-IM every 3 months, a copper IUD, or a LNG implant with random block sizes between 15 and 30, stratified by site. Participants were assigned using an online randomisation system, which was accessed for each randomisation by study staff at each site. The primary endpoint was incident HIV infection in the modified intention-to-treat population, including all randomised participants who were HIV negative at enrolment and who contributed at least one HIV test. The primary safety endpoint was any serious adverse event or any adverse event resulting in method discontinuation, until the trial exit visit at 18 months and was assessed in all enrolled and randomly assigned women. This study is registered with ClinicalTrials.gov, number NCT02550067. FINDINGS: Between Dec 14, 2015, and Sept 12, 2017, 7830 women were enrolled and 7829 were randomly assigned to the DMPA-IM group (n=2609), the copper IUD group (n=2607), or the LNG implant group (n=2613). 7715 (99%) participants were included in the modified intention-to-treat population (2556 in the DMPA-IM group, 2571 in the copper IUD group, and 2588 in the LNG implant group), and women used their assigned method for 9567 (92%) of 10 409 woman-years of follow-up time. 397 HIV infections occurred (incidence 3·81 per 100 woman-years [95% CI 3·45-4·21]): 143 (36%; 4·19 per 100 woman-years [3·54-4·94]) in the DMPA-IM group, 138 (35%: 3·94 per 100 woman-years [3·31-4·66]) in the copper IUD group, and 116 (29%; 3·31 per 100 woman-years [2·74-3·98]) in the LNG implant group. In the modified intention-to-treat analysis, the hazard ratios for HIV acquisition were 1·04 (96% CI 0·82-1·33, p=0·72) for DMPA-IM compared with copper IUD, 1·23 (0·95-1·59, p=0·097) for DMPA-IM compared with LNG implant, and 1·18 (0·91-1·53, p=0·19) for copper IUD compared with LNG implant. 12 women died during the study: six in the DMPA-IM group, five in the copper IUD group, and one in the LNG implant group. Serious adverse events occurred in 49 (2%) of 2609 participants in the DMPA-IM group, 92 (4%) of 2607 participants in the copper IUD group, and 78 (3%) of 2613 participants in the LNG implant group. Adverse events resulting in discontinuation of the randomly assigned method occurred in 109 (4%) women in the DMPA-IM group, 218 (8%) women in the copper IUD group, and 226 (9%) women in the LNG implant group (p<0·0001 for DMPA-IM vs copper IUD and for DMPA-IM vs LNG implant). 255 pregnancies occurred: 61 (24%) in the DMPA-IM group, 116 (45%) in the copper IUD group, and 78 (31%) in the LNG implant group. 181 (71%) pregnancies occurred after discontinuation of randomly assigned method. INTERPRETATION: We did not find a substantial difference in HIV risk among the methods evaluated, and all methods were safe and highly effective. HIV incidence was high in this population of women seeking pregnancy prevention, emphasising the need for integration of HIV prevention within contraceptive services for African women. These results support continued and increased access to these three contraceptive methods. FUNDING: Bill & Melinda Gates Foundation, US Agency for International Development and the President's Emergency Plan for AIDS Relief, Swedish International Development Cooperation Agency, South African Medical Research Council, and UN Population Fund. Contraceptive supplies were donated by the Government of South Africa and US Agency for International Development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(19)31288-7

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Trial profile DMPA-IM=intramuscular depot medroxyprogesterone acetate. IUD=intrauterine device. LNG=levonorgestrel. *Per-site enrolment numbers are detailed in the appendix (p 19). †One enrollee (from South Africa) was discovered 2 days after randomisation to have been younger than 18 years but had entered the trial without parental or guardian consent and was immediately exited.
Figure 1 Trial profile DMPA-IM=intramuscular depot medroxyprogesterone acetate. IUD=intrauterine device. LNG=levonorgestrel. *Per-site enrolment numbers are detailed in the appendix (p 19). †One enrollee (from South Africa) was discovered 2 days after randomisation to have been younger than 18 years but had entered the trial without parental or guardian consent and was immediately exited.CC BY · PubMed Central
Figure 2 Contraceptive use by group DMPA-IM=intramuscular depot medroxyprogesterone acetate. IUD=intrauterine device. LNG=levonorgestrel. *Other non-hormonal methods accounted for less than 0·1% of contraceptive use during follow-up.
Figure 2 Contraceptive use by group DMPA-IM=intramuscular depot medroxyprogesterone acetate. IUD=intrauterine device. LNG=levonorgestrel. *Other non-hormonal methods accounted for less than 0·1% of contraceptive use during follow-up.CC BY · PubMed Central
Figure 3 Kaplan-Meier curves for the primary, modified intention-to-treat analysis DMPA-IM=intramuscular depot medroxyprogesterone acetate. HR=hazard ratio. IUD=intrauterine device. LNG=levonorgestrel.
Figure 3 Kaplan-Meier curves for the primary, modified intention-to-treat analysis DMPA-IM=intramuscular depot medroxyprogesterone acetate. HR=hazard ratio. IUD=intrauterine device. LNG=levonorgestrel.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 299

Metadata

Authors
Ahmed, K., Baeten, J. M., Beksinska, M., Bekker, L.-G., Bukusi, E. A., Donnell, D., Gichangi, P. B., Heller, K. B., Hofmeyr, G. J., Justman, J., Kasaro, M. P., Kiarie, J., Louw, C., Mastro, T. D., Morrison, C. S., Mugo, N. R., Nair, G., Nanda, K., Nhlabatsi, Z., Onono, M., Palanee-Phillips, T., Pleaner, M., Rees, H., Singata-Madliki, M., Scoville, C. W., Selepe, R. A. P., Shears, K., Sibiya, S., Smit, J., Steyn, P. S., Stringer, J., Taylor, D., Thomas, K. K., & Welch, J. D.
Affiliations
University of Washington (US)
Corresponding author
Baeten, Jared M
Venue
The Lancet
Publisher
Elsevier BV
Published
2019-07
Volume
394
Issue
10195
Pages
303-313
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2952324645
Cited by
299
References
18
Citations by year
2026: 13 · 2025: 19 · 2024: 24 · 2023: 33 · 2022: 36 · 2021: 69 · 2020: 78 · 2019: 25
FWCI
47.88
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • United States Agency for International Development
  • South African Medical Research Council
  • Medical Research Council
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
Keywords
HIV incidence, HIV acquisition, depot medroxyprogesterone acetate, copper intrauterine device, levonorgestrel implants, hormonal contraception, contraceptive safety, HIV prevention, young women, sub-Saharan Africa, adverse events, Swaziland, Kenya, South Africa, Zambia, informed consent
MeSH terms
Adolescent, Adult, Family Planning Services, Female, Humans, Intrauterine Devices, Copper, Kenya, Pregnancy, South Africa, Eswatini, Zambia, HIV Infections, Incidence, Levonorgestrel, Medroxyprogesterone Acetate, Young Adult, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. https://app.cochat.ai/papers/10.1016/s0140-6736(19)31288-7
The paper
Ahmed, K., Baeten, J. M., Beksinska, M., Bekker, L.-G., Bukusi, E. A., Donnell, D., Gichangi, P. B., Heller, K. B., Hofmeyr, G. J., Justman, J., Kasaro, M. P., Kiarie, J., Louw, C., Mastro, T. D., Morrison, C. S., Mugo, N. R., Nair, G., Nanda, K., Nhlabatsi, Z., . . . Welch, J. D. (2019). HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. The Lancet. https://doi.org/10.1016/s0140-6736(19)31288-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.